Proteomics International Laboratories Ltd Total Liabilities
Proteomics International Laboratories Ltd total liabilities. Based on the latest financial reports, Proteomics International Laboratories Ltd (PIQ) has total liabilities worth AU$4.09 Million AUD (≈ $2.90 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PIQ cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Proteomics International Laboratories Ltd (2014–2025)
Total liabilities of Proteomics International Laboratories Ltd from 2014 to 2025. This chart illustrates how Proteomics International Laboratories Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Proteomics International Laboratories Lt to see how much of total assets are deployed in long-term investments.
Proteomics International Laboratories Ltd Competitors by Total Liabilities
The table below lists competitors of Proteomics International Laboratories Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baillie Gifford US Growth Trust PLC
LSE:USA
|
UK | GBX39.47 Million |
|
Femasys Inc
NASDAQ:FEMY
|
USA | $8.26 Million |
|
Hookipa Pharma Inc
NASDAQ:HOOK
|
USA | $24.02 Million |
|
Energisme
PA:ALNRG
|
France | €13.29 Million |
|
Prodigy Gold NL
AU:PRX
|
Australia | AU$2.15 Million |
|
Oncosil Medical Ltd
AU:OSL
|
Australia | AU$3.29 Million |
|
IRIDEX Corporation
NASDAQ:IRIX
|
USA | $23.62 Million |
|
Goodyear Lastikleri TAS
IS:GOODY
|
Turkey | TL12.32 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Proteomics International Laboratories Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PIQ current and non-current assets.
Liquidity & Leverage Metrics
Proteomics International Laboratories Ltd Total Liabilities Ratios Explained
Proteomics International Laboratories Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.61 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Proteomics International Laboratories Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Proteomics International Laboratories Ltd (2014–2025)
The table below shows the annual total liabilities of Proteomics International Laboratories Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$1.81 Million ≈ $1.28 Million |
+11.58% |
| 2024-06-30 | AU$1.63 Million ≈ $1.15 Million |
-7.20% |
| 2023-06-30 | AU$1.75 Million ≈ $1.24 Million |
-12.49% |
| 2022-06-30 | AU$2.00 Million ≈ $1.42 Million |
+102.21% |
| 2021-06-30 | AU$990.19K ≈ $700.62K |
-11.34% |
| 2020-06-30 | AU$1.12 Million ≈ $790.22K |
+75.99% |
| 2019-06-30 | AU$634.59K ≈ $449.01K |
-22.45% |
| 2018-06-30 | AU$818.30K ≈ $579.00K |
-36.04% |
| 2017-06-30 | AU$1.28 Million ≈ $905.19K |
+53.92% |
| 2016-06-30 | AU$831.17K ≈ $588.11K |
+14.33% |
| 2015-06-30 | AU$727.01K ≈ $514.41K |
+147.54% |
| 2014-06-30 | AU$293.69K ≈ $207.81K |
-- |
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more